Edit

Acer Therapeutics

http://www.acertx.com/

Last activity: 05.08.2024

Active

Categories: AdTechAppBioTechCosmeticDataDevelopmentDrugFoodTechMedTechProduct

Acer Therapeutics is passionate about developing therapies for patients with serious, ultra-rare diseases with critical unmet medical need.

Likes

217

Followers

581

Mentions

Location: United States, Massachusetts, Newton

Employees: 11-50

Phone: +1 617-225-7700

Total raised: $56.65M

Founded date: 2013

Twitter

Facebook

Investors 2

Date	Name	Website
11.04.2022	SWK Holdin...	swkhold.co...
-	TVM Capita...	tvm-lifesc...

Funding Rounds 2

Date	Series	Amount	Investors
07.03.2022	-	$48.5M	-
10.05.2016	Series B	$8.15M	-

Mentions in press and media 21

Date	Title	Description
05.08.2024	Relief Therapeutics secures up to $11 million	Relief Therapeutics, which focuses on the development and commercialization of patent-protected drugs for rare and ultra-rare diseases, announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK), a wholly-owned ...
26.06.2023	Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder	/EIN News/ -- Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a ...
26.06.2023	Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder	-
26.10.2022	Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)	Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038 /EIN News/ -- NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a cli...
06.05.2022	Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference	NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) ("Relief"), today ...
07.03.2022	Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities	NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with...
08.10.2021	Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation	Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) ...
07.10.2021	Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation	EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation 07-Oct-2021 / 07:00 CET/CEST Release of an ad hoc announcemen...
07.10.2021	Acer Therapeutics : Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 (Form 8-K)	Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND - October 7, 2021 - Acer Therapeutics Inc. (Nasdaq: ACER) ("Ace...
06.10.2021	Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders	NEWTON, Mass. and GENEVA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Food...
27.05.2021	Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA	NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening dis...
22.03.2021	Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Diseas...	Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA, SWITZERLAND and NEWTON, MA – March 22, 2021 – RELIEF ...
16.01.2021	ACER THERAPEUTICS INC. ACER THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	Item 7.01. Regulation FD. The Company has updated its Corporate Presentation that will be available on the Investor Relations page of the Company's website at https://acertx.com/investor-relations and will be used at investor and other meet...
16.01.2021	ACER THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	Item 7.01. Regulation FD. The Company has updated its Corporate Presentation that will be available on the Investor Relations page of the Company's website at https://acertx.com/investor-relations and will be used at investor and other meet...
25.06.2019	Acer has to conduct new trial of rare disease drug, FDA says	Following the announcement, shares of the company were down nearly 78 percent on the Nasdaq Tuesday afternoon. “We remain committed to working closely with the FDA to fully understand its response,” Acer CEO Chris Schelling said in a statem...
18.01.2018	The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book	Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US FDA approval process before trumpeting an $89,000 annual price. The move, criticized by l...
10.05.2016	Acer Therapeutics Closes $8.15M Series B Funding Round	Acer Therapeutics Inc., a Cambridge, MA-based pharmaceutical company developing therapies for serious rare diseases, closed its $8.15m Series B round. The round was led by TVM Life Science Venture VII, with participation from Bukwang Pharm....
02.04.2015	Cambridge startup raises $2.1M to develop first drug for Maple Syrup Urine Disease	MSUD patients carry a genetic defect that prevents branched chain amino acids from being broken down. These, and their corresponding ketoacids, build up abnormally in the system – lending the maple syrup smell to the urine. This also trigge...
-	Acer has to conduct new trial of rare disease drug, FDA says	Shares of a company developing drugs to treat rare diseases dove for the abyss Tuesday as the Food and Drug Administration rejected the company’s regulatory approval application for a rare disease treatment. Acer Therapeutics, headquartered...
-	Healthcare hires of note	Igentify, a digital health company that’s developed a platform to securely streamline the genetic testing and results process, has added three experts to its leadership team. Danielle Gutter has been named vice president of global sales. He...
-	Cambridge startup raises $2.1M to develop first drug for Maple Syrup Urine Disease	Cambridge startup Acer Therapeutics is developing the first therapy for a rare inherited condition called Maple Syrup Urine Disease. Known for causing neurological and social impairment, MSUD gets its unique name from the urine’s distinctiv...

Acer Therapeutics

Investors 2

Funding Rounds 2

Mentions in press and media 21

Reviews 0